101 related articles for article (PubMed ID: 21799030)
1. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.
Dondossola E; Gasparri AM; Colombo B; Sacchi A; Curnis F; Corti A
Cancer Res; 2011 Sep; 71(17):5881-90. PubMed ID: 21799030
[TBL] [Abstract][Full Text] [Related]
2. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
Curnis F; Sacchi A; Corti A
J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage.
Ferrero E; Scabini S; Magni E; Foglieni C; Belloni D; Colombo B; Curnis F; Villa A; Ferrero ME; Corti A
FASEB J; 2004 Mar; 18(3):554-6. PubMed ID: 14734634
[TBL] [Abstract][Full Text] [Related]
4. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
5. Synergistic damage of tumor vessels with ultra low-dose endothelial-monocyte activating polypeptide-II and neovasculature-targeted tumor necrosis factor-alpha.
Crippa L; Gasparri A; Sacchi A; Ferrero E; Curnis F; Corti A
Cancer Res; 2008 Feb; 68(4):1154-61. PubMed ID: 18281491
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW; Fiedler W; Desar IM; van Asten JJ; Marréaud S; Lacombe D; Govaerts AS; Bogaerts J; Lasch P; Timmer-Bonte JN; Lambiase A; Bordignon C; Punt CJ; Heerschap A; van Herpen CM
Clin Cancer Res; 2010 Feb; 16(4):1315-23. PubMed ID: 20145168
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
[TBL] [Abstract][Full Text] [Related]
8. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer.
Bertilaccio MT; Grioni M; Sutherland BW; Degl'Innocenti E; Freschi M; Jachetti E; Greenberg NM; Corti A; Bellone M
Prostate; 2008 Jul; 68(10):1105-15. PubMed ID: 18437689
[TBL] [Abstract][Full Text] [Related]
9. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
[TBL] [Abstract][Full Text] [Related]
10. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Sacchi A; Gasparri A; Gallo-Stampino C; Toma S; Curnis F; Corti A
Clin Cancer Res; 2006 Jan; 12(1):175-82. PubMed ID: 16397040
[TBL] [Abstract][Full Text] [Related]
11. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
Corti A; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.
Lejeune FJ; Rüegg C
Bull Cancer; 2006 Aug; 93(8):E90-100. PubMed ID: 16935777
[TBL] [Abstract][Full Text] [Related]
13. Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-alpha-elicited endothelial activation.
Di Comite G; Rossi CM; Marinosci A; Lolmede K; Baldissera E; Aiello P; Mueller RB; Herrmann M; Voll RE; Rovere-Querini P; Sabbadini MG; Corti A; Manfredi AA
J Leukoc Biol; 2009 Jan; 85(1):81-7. PubMed ID: 18832606
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.
van der Veen AH; de Wilt JH; Eggermont AM; van Tiel ST; Seynhaeve AL; ten Hagen TL
Br J Cancer; 2000 Feb; 82(4):973-80. PubMed ID: 10732774
[TBL] [Abstract][Full Text] [Related]
15. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
J Cell Biochem; 1994 Sep; 56(1):52-61. PubMed ID: 7806592
[TBL] [Abstract][Full Text] [Related]
16. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
17. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
Halin C; Gafner V; Villani ME; Borsi L; Berndt A; Kosmehl H; Zardi L; Neri D
Cancer Res; 2003 Jun; 63(12):3202-10. PubMed ID: 12810649
[TBL] [Abstract][Full Text] [Related]
18. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan.
Bauer TW; Gutierrez M; Dudrick DJ; Li J; Blair IA; Menon C; Fraker DL
Surgery; 2003 Apr; 133(4):420-8. PubMed ID: 12717360
[TBL] [Abstract][Full Text] [Related]
19. Chromogranin A (CGA)-derived polypeptide (CGA
Luo L; Liu S; Zhang D; Wei F; Gu N; Zeng Y; Chen X; Xu S; Liu S; Xiang T
Peptides; 2020 Sep; 131():170297. PubMed ID: 32380199
[TBL] [Abstract][Full Text] [Related]
20. The IL-6/sIL-6R treatment of a malignant melanoma cell line enhances susceptibility to TNF-alpha-induced apoptosis.
Wagley Y; Yoo YC; Seo HG; Rhee MH; Kim TH; Kang KW; Nah SY; Oh JW
Biochem Biophys Res Commun; 2007 Mar; 354(4):985-91. PubMed ID: 17274948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
